PR Newswire·Nov 12, 2026, 4:30 PM ET

Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates

Azitra reported Q3 2026 financial results & provided business updates for the quarter ended September 30, 2026.
Ex vivo studies of ATR-COSF showed a single application reduced fine lines & wrinkles by approximately 50% after 48 hours while improving skin elasticity.
Cohort 1 of the ATR-04 Phase 1/2 trial was completed, with a safety review committee recommending progression to Cohort 2.
ATR-04 trial eligibility was expanded to include patients with KRAS and MEK inhibitor-associated rash, including those with neurofibromatosis type 1.
ATR-04 Cohort 2 will enroll approximately 24 patients receiving once-daily treatment for 28 days.
Topline data from ATR-04 Cohort 1 is anticipated in Q4 2026, with initial results from the first-in-human ATR-COSF cosmetic study expected by year-end.
R&D expenses for the quarter were $1.3 million, compared to $1.2 million in the same period in 2025.
G&A expenses remained at $1.6 million for the quarter, consistent with the comparable period in 2025.
Net loss for the quarter was $3.0 million, an increase from $2.8 million in the same period in 2025.
Cash and cash equivalents totaled $3.8 million as of September 30, 2026.
Institutional investors from the earlier 2026 financing may invest an additional $5.25 million to $10.5 million following ATR-COSF result announcements.